Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 4,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Recruiting Phase 1Phase 2 Interventional

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

NCT01306019
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency (XSCID)
Interventions
Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector, Busulfan, Palifermin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 12:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

NCT00490100
View directory record Official record
Conditions
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions
Increlex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 3 Interventional

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

NCT00120393
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 19, 2026, 12:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Load in Blood and Lymph Tissues in People Living With HIV

NCT00001316
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1992
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 3 Interventional

Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination

NCT00002416
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine, Lamivudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
St. Petersburg, Florida • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility

NCT00002006
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Zidovudine, Sargramostim
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 12:27 PM EDT
Completed No phase listed Observational

Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

NCT01985399
View directory record Official record
Conditions
HIV, AIDS
Interventions
Neuropsychological testing
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Functional Interval Training for Veterans Exercising Through Telehealth.

NCT04103593
View directory record Official record
Conditions
HIV Infection
Interventions
exercise training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Motiv82Change: an HIV Prevention Study for Young Latino Men

NCT00877695
View directory record Official record
Conditions
HIV Infections
Interventions
Entre Culturas: Navigating Culture, Identity, and HIV Risk
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 19, 2026, 12:27 PM EDT
Completed No phase listed Observational

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

NCT01180075
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV), tenofovir/emtricitabine (TDF/FTC), Atazanavir (ATV), Ritonavir, Phlebotomy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir

NCT00486330
View directory record Official record
Conditions
HIV Infections
Interventions
Buprenorphine, Tipranavir and ritonavir
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 2 Interventional Results available

Effect of Cenicriviroc on HIV Neurocognitive Impairment

NCT02128828
View directory record Official record
Conditions
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
Interventions
cenicriviroc
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

NCT00485264
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir poloxamer film coated tablet, Raltegravir chewable tablet, Raltegravir oral granules for suspension (20 mg/mL)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
29
States / cities
Alhambra, California • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

NCT04799353
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Budigalimab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

NCT00002436
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Zalcitabine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

NCT00630734
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Pravastatin, Darunavir, Ritonavir, Washout
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 19, 2026, 12:27 PM EDT
Approved For Marketing No phase listed Expanded access

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

NCT00097799
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Timeline
Started 2004
U.S. locations
115
States / cities
Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Suubi4Stigma: Addressing HIV-Associated Stigma Among Adolescents

NCT04528732
View directory record Official record
Conditions
HIV/AIDS
Interventions
Group Cognitive Behavioral Therapy (G-CBT), Multiple Family Group (MFG)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years to 14 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

2nd AC+: New Village Model

NCT04323176
View directory record Official record
Conditions
Aging, Hiv, Loneliness, Social Isolation
Interventions
Village Model implementation
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

NCT00000818
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 19, 2026, 12:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mental Ability Challenge Study in Adults With and Without HIV

NCT03244488
View directory record Official record
Conditions
HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions
Scopolamine Injectable Product, Mecamylamine Pill
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Not applicable Interventional

Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects

NCT00002018
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3
Drug
Lead sponsor
Interferon Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 12:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolic Abnormalities in HIV Infected and Uninfected Young Women

NCT00067587
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Glucose Intolerance
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 19, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

The Use of Reiki for Patients With Advanced AIDS

NCT00032721
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Reiki; Subtle energy therapy
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 19, 2026, 12:27 PM EDT